In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 36063558.
- Also identified by DOI 10.7326/J22-0063.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuen BL, Oshima M, Agarwal R, et al. <b>Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials.</b> Circulation. 2022;145:1460-70. 35394821.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hyperkalemia
- Hypokalemia
- Sodium-Glucose Transporter 2 Inhibitors